-
421
Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America
Published 2010-05-01Get full text
Article -
422
-
423
-
424
-
425
-
426
-
427
-
428
Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?
Published 2018-06-01“…In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel (Plavix©, Bristol-Myers Squibb, New York, NY) became the mainstay of therapy. …”
Get full text
Article -
429
Intravenous paracetamol and intraocular pressure reduction: mannitol may also be involved
Published 2016-09-01“…Karel Allegaert1,2 1Intensive Care, Department of Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands; 2Department of Development and Regeneration, KU Leuven, BelgiumI read, with great interest, the paper on the intraocular pressure-lowering properties of intravenous paracetamol (acetaminophen) recently published in this journal by van den Heever and Meyer.1 The authors documented a decrease from baseline in mean intraocular pressure of 15.7% in a 6-hour time interval following intravenous paracetamol (1 g Perfalgan®, Bristol-Myers Squibb, New York, NY, USA) administration. …”
Get full text
Article -
430
-
431
-
432
-
433
News at Six: Hepatitis C Special
Published 2014-05-01“…This Bristol Myers Squibb-sponsored symposium was chaired by Mark Thursz, who oversaw a novel news bulletin-themed symposium with sessions provided by a distinguished, international team of roving reporters; Charles Gore from the World Hepatitis Alliance, Jean-Michel Pawlotsky from France, Alessandra Mangia from Italy, Ashley Brown and Graham Foster from London, Heiner Wedemeyer from Germany, and Rafael Esteban from Spain.…”
Get full text
Article -
434
658 Preoperative short course radiotherapy with envafolimab, endostatin and SOX regimen in locally advanced gastric
Published 2023-11-01Article -
435
-
436
-
437
Current status and future directions of high-throughput ADME screening in drug discovery
Published 2020-06-01Get full text
Article -
438
Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review
Published 2012“…Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. …”
Journal article -
439
-
440